Renaud Ronald C JR 4

What Happened Renaud Ronald C. Jr., a director of Upstream Bio, was granted a derivative award for 17,096 shares (reported as acquisition code A) on June 9, 2026. The filing reports an acquisition price of $0.00 and a total reported value of $0. The award is described in the filing as an option-like grant (the footnote refers to "shares underlying this option").

Key Details

• Transaction date: 2026-06-09; Form 4 filed 2026-06-11 (appears timely).
• Transaction type/code: A = Award/Grant (derivative security).
• Quantity and price: 17,096 shares/options at $0.00 (total $0 reported).
• Vesting: Footnote F1 — vests in full upon the earlier of (i) June 9, 2027 or (ii) the date of the next Annual Meeting, subject to the reporting person’s continued service.
• Shares owned after transaction: Not specified in the filing.
• No indication of a 10b5-1 plan, tax-withholding sale, or late filing in the document.

Context This was a compensation grant (derivative/option-style award), not an open-market purchase or sale. Such grants do not typically represent immediately tradable shares — the underlying shares will become vested per the schedule noted and may require exercise before being sold. Awards to directors are common as part of compensation and should be read as a compensation event rather than a direct market sentiment signal.